Asthma control in the United States: Relationships between short-acting β 2 -agonist and systemic corticosteroid use.
Geoffrey ChuppKevin R MurphyHitesh N GandhiIleen GilbertEugene R BleeckerPublished in: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024)
High symptom burden and SCS exposures are not limited to severe asthma but are also characteristic of patients treated for mild to moderate disease. Both impairment and risk assessments are required to understand the full extent of uncontrolled asthma across disease severities.